

The use of molecular line probe assays
for the detection of resistance
to isoniazid and rifampicin

MDR-TB
DIAGNOSTIC TESTS
PULMONARY TB
RIFAMPICIN
DIAGNOSIS
RESISTANCE
POLICY UPDATE
DRUG-RESISTANCE
ISONIAZID
TUBERCULOSIS
FIRST-LINE TB DRUGS
RECOMMENDATIONS
RAPID TB TEST
PERFORMANCE
RESISTANCE
MYCOBACTERIUM
RIFAMPICIN

The use of molecular line probe assays
for the detection of resistance
to isoniazid and rifampicin

Policy update



World Health
Organization

WHO Library Cataloguing-in-Publication Data

The use of molecular line probe assay for the detection of resistance to isoniazid and rifampicin: policy update.

Contents: web annex 1: GRADE summary of findings tables – web annex 2: Evidence to recommendations tables – web annex 3: references to studies included and excluded from the review 1. Tuberculosis, Multidrug-resistant. 2. Antitubercular Agents. 3. Rifampin - pharmacology. 4. Isoniazid – pharmacology. 5. Drug Resistance. 6. Molecular Probes. 7. Guideline.

I. World Health Organization.

ISBN 978 92 4 151126 1 (NLM classification: WF 310)

Subject headings are available from WHO institutional repository

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by GPS Publishing

Printed in Spain

WHO/HTM/TB/2016.12

Contents

EXECUTIVE SUMMARY	x
1. BACKGROUND	2
1.1 INDEX TESTS	3
2. METHODS	4
2.1 EVIDENCE SYNTHESIS	4
2.2 GUIDELINE DEVELOPMENT GROUP MEETING	6
2.3 EXTERNAL REVIEW GROUP	7
3. SCOPE	7
3.1 TARGET AUDIENCE	7
4. EVIDENCE BASE FOR POLICY FORMULATION	8
4.1 QUALITY OF INCLUDED STUDIES	10
4.1.1 RISK OF BIAS FOR DETECTING RIFAMPICIN RESISTANCE	10
4.1.2 RISK OF BIAS FOR DETECTING ISONIAZID RESISTANCE	11
4.1.3 RISK OF BIAS FOR DETECTING <i>MYCOBACTERIUM TUBERCULOSIS</i> COMPLEX	11
4.2 ACCURACY FOR DETECTING RIFAMPICIN RESISTANCE	12
4.2.1 DIRECT TESTING FOR DETECTING RIFAMPICIN RESISTANCE	12
4.2.2 INDIRECT TESTING FOR DETECTING RIFAMPICIN RESISTANCE	16
4.2.3 COMPARISON OF DIAGNOSTIC ACCURACY: DIRECT VERSUS INDIRECT TESTING	18
4.2.4 ACCURACY OF DETECTING RIFAMPICIN RESISTANCE COMPARED WITH A COMPOSITE REFERENCE STANDARD	19
4.3 ACCURACY FOR DETECTING ISONIAZID RESISTANCE	21
4.3.1 DIRECT TESTING FOR DETECTING ISONIAZID RESISTANCE	21
4.3.2 INDIRECT TESTING FOR DETECTING ISONIAZID RESISTANCE	23
4.3.3 COMPARISON OF DIAGNOSTIC ACCURACY: DIRECT VERSUS INDIRECT TESTING	26
4.3.4 ACCURACY FOR DETECTING ISONIAZID RESISTANCE COMPARED WITH A COMPOSITE REFERENCE STANDARD	27
4.4 ACCURACY IN DIAGNOSING MDR-TB	29
4.5 DIAGNOSING <i>MYCOBACTERIUM TUBERCULOSIS</i> COMPLEX INFECTION	29

5. SUMMARY: FROM EVIDENCE TO RECOMMENDATIONS	30
5.1 USING LINE PROBE ASSAYS TO DETECT RESISTANCE TO RIFAMPICIN	30
5.2 USING LINE PROBE ASSAYS TO DETECT RESISTANCE TO ISONIAZID	31
5.3 USING LINE PROBE ASSAYS TO DETECT MDR-TB	32
6. WHO'S POLICY RECOMMENDATIONS	33
7. IMPLEMENTATION CONSIDERATIONS	33
7.1 PLANS FOR DISSEMINATING WHO'S POLICY GUIDANCE ON USING LINE PROBE ASSAYS	34
8. RESEARCH NEEDS	34
9. ONLINE ANNEXES	35
ANNEX 1. STUDIES INCLUDED IN THE REVIEW OF THE DIAGNOSTIC ACCURACY OF LINE PROBE ASSAYS	36

Acknowledgements

This document was prepared by Christopher Gilpin and Alexei Korobitsyn with input from Karin Weyer (all at WHO's Global TB Programme) on the basis of consensus agreed at a Guideline Development Group meeting convened by WHO in Montreux, Switzerland, on 2 March 2016.

WHO Steering Group

Christopher Gilpin, Karin Weyer, Alexei Korobitsyn, Wayne van Gemert and Fuad Mirzayev (all at WHO's Global TB Programme)

Chair of the WHO Guideline Development Group

Holger Schünemann (McMaster University, Canada)

GRADE methodologist of the WHO Guideline Development Group

Holger Schünemann (McMaster University, Canada)

Members of the WHO Guideline Development Group

Gavin Churchyard (The Aurum Institute, South Africa), Daniela Maria Cirillo (HSR San Raffaele Scientific Institute/TB Supranational Reference Laboratory, Italy), Chris Coulter (Queensland Mycobacterium Reference Laboratory, Australia), Greg Fox (University of Sydney, Australia), Moses Joloba (National Reference Laboratory of the National TB and Leprosy Programme, Uganda), James Posey (Centers for Disease Control and Prevention, United States of America), Michael Rich (Partners in Health, United States of America), Leen Rigouts (Institute of Tropical Medicine, Belgium), Thomas M. Shinnick (independent consultant, United States of America), Rebecca Tadokera (Human Sciences Research Council, South Africa) (unable to attend), Marie Alice Telles (independent tuberculosis laboratory consultant for the Pan American Health Organization, Brazil), Francis Varaine (Médecins Sans Frontières, France)

Systematic review authors

Ruvandhi R. Nathavitharana (Beth Israel Deaconess Medical Center, United States), Patrick Cudahy (Yale Medical Center, United States), Samuel G. Schumacher (FIND [Foundation for Innovative New Diagnostics], Switzerland), Karen Steingart (Liverpool School of Tropical Medicine, England), Madhukar Pai (McGill University, Canada), Claudia M. Denking (FIND, Switzerland)

Observers

Sevim Ahmedov (United States Agency for International Development, United States), Emmanuelle Cambau (Groupe Hospitalier Lariboisière-Fernand Widal, France), David Dolinger (FIND), Miranda Langendam (University of Amsterdam, The Netherlands), Thomas Schön (Kalmar County Hospital and Linköping University, Sweden), Belay Tessema (FIND, Switzerland)

External Review Group

Heather Alexander (Centers for Disease Control and Prevention, United States), Martina Casenghi (Médecins Sans Frontières Access Campaign, Switzerland), Kathleen England (KNCV Tuberculosis Foundation, The Netherlands), Rumina Hasan (TB Supranational Reference Laboratory Pakistan, Aga Khan University, Pakistan), Nazir Ismail (TB Supranational Reference Laboratory, National Institute of Communicable Diseases, South Africa), Beatrice Lopez (Buenos Aires TB Supranational Reference Laboratory, Argentina), Richard Lumb (Adelaide TB Supranational Reference Laboratory, Australia), Satoshi Mitarai (Japan Anti-Tuberculosis Association, Japan), Alaine Umubyeyi Nyaruhirira (Management Sciences for Health, South Africa), Rohit Sarin (LRS Institute of TB and Respiratory Diseases, India), Alena Shrahina (National TB Programme, Belarus),

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26771

